Emergent Biosolutions Inc. Stock
Emergent Biosolutions Inc. took a tumble today and lost -€0.440 (-3.950%).
Emergent Biosolutions Inc. is currently one of the favorites of our community with 8 Buy predictions and no Sell predictions.
With a target price of 13 € there is a positive potential of 22.35% for Emergent Biosolutions Inc. compared to the current price of 10.63 €.
Our community identified positive and negative aspects for Emergent Biosolutions Inc. stock for the coming years. 1 users see the criterium "Company culture" as a plus for the Emergent Biosolutions Inc. stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Emergent Biosolutions Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
G***** c******* t* c**********
Cons
?
C******** o* t** e**********
?
S********** s********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Emergent Biosolutions Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Emergent Biosolutions Inc. | -3.950% | -3.057% | 9.266% | 10.264% | 2.262% | -15.204% | -87.500% |
| Ironwood Pharmaceuticals | 1.740% | -9.794% | 14.379% | -20.455% | 31.579% | -66.072% | -63.351% |
| Novocure Ltd | -4.380% | 3.488% | 7.181% | -54.591% | 7.322% | -86.197% | -91.552% |
| Iovance Biotherapeutics Inc. | -2.020% | -1.534% | 9.357% | -67.049% | -13.427% | -64.125% | -94.958% |
Comments
Emergent Biosolutions (NYSE:EBS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Show more
Ratings data for EBS provided by MarketBeat
Emergent Biosolutions (NYSE:EBS) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating.
Show more
Ratings data for EBS provided by MarketBeat
Emergent Biosolutions (NYSE:EBS) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating.
Show more
Ratings data for EBS provided by MarketBeat